Compare Freeport-McMoRan Inc (FCX) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freeport-McMoRan Inc vs Medtronic PLC — how do they compare? Freeport-McMoRan Inc trades at $73.85 (market cap $102.16B), while Medtronic PLC trades at $88.46 (market cap $112.24B). The key difference: Freeport-McMoRan Inc and Medtronic PLC are close in size by market cap, and Medtronic PLC pays the higher dividend (3.28%). Which is the better fit depends on your goals — on Pluang, investors hold Freeport-McMoRan Inc for 69 Days and Medtronic PLC for 63 Days on average.
| FCX | MDT | |
|---|---|---|
Market Cap | $102.16B | $112.24B |
Volume | 9,047,971 | 105,663,236 |
Sector | Basic Materials | Health |
52-Week High | $79.91 | $105.35 |
52-Week Low | $38.65 | $73.75 |
Typical Hold Time | 69 Days | 63 Days |
Enterprise Value | $108.44B | $131.58B |
Dividend Yield | 0.84% | 3.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCX trades at $73.29, up 1.98% on the day, with a bearish technical signal but strong fundamental support. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results pending. Revenue is stable at $25.9B (2025), and net income margin improved to 11.38%. Analyst consensus is a Buy (60.97%), with a price target of $73.27. Recent news highlights copper demand growth driven by AI and data centers, positioning FCX to benefit.
FCX offers exposure to rising copper demand, supported by operational efficiency and expansion projects. Risks include cost pressures and regulatory scrutiny. The stock's valuation metrics (P/E 34.87, P/S 3.97) suggest premium pricing, requiring sustained earnings growth to justify upside. Institutional sentiment remains positive, but investors should monitor Q3 earnings and copper price trends.
Medtronic (MDT) trades at $87.80, up 2.68% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a 13.93% net income margin and consistent dividend growth over 49 years. Revenue growth accelerated to $33.54B in 2025, and analyst consensus targets $97.80, implying 11% upside. Recent news highlights regulatory approvals for medical devices and a $4B MiniMed exchange offer.
MDT offers value with a 3.2% dividend yield and reasonable valuation (P/E 21.6), but faces headwinds from technical bearishness and rising debt. The stock's appeal hinges on execution of growth initiatives in cardiovascular and neuroscience segments, though competitive and macroeconomic risks persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
